On a DART-filed annual basis, revenue fell from KRW 8.73 billion in 2022 to KRW 6.58 billion in 2023 (down 24.6% year on year), edged up to KRW 6.72 billion in 2024 (up 2.1%), and then dropped to KRW 5.77 billion in 2025 (down 14.2%). Among 2022–2025, 2022 was the largest year and 2025 the smallest.
The operating loss was KRW 5.73 billion in 2022, KRW 5.77 billion in 2023 (losses widened), KRW 1.9 billion in 2024 (losses narrowed) and KRW 3.32 billion in 2025 (losses widened), marking four consecutive years of losses from 2022 to 2025.
The operating margin was -65.7% in 2022, -87.7% in 2023, -28.3% in 2024 and -57.6% in 2025, so 2024 had the smallest loss margin.
Net income attributable to controlling shareholders moved from a net loss of KRW 4.8 billion in 2022 and KRW 3.88 billion in 2023 to a profit of KRW 12.3 billion in 2024, then back to a net loss of KRW 4.04 billion in 2025.
The 2024 swing to profit was far larger than the operating loss, which points to a large non-operating contribution. The company attributed the 2024 improvement to cost reduction, organizational efficiency and the exit from low-margin product sales such as peripherals and disposable reagents.
In 2025, the company said a deterioration in profitability widened the operating loss and that a fair-value loss on financial assets, tied to a fall in the value of equity investments in other companies, was recognized.
The debt ratio fell from 19.5% in 2022 to 6.0% in 2025, with total equity of KRW 23 billion and total liabilities of KRW 1.39 billion at end-2025. Operating cash flow was negative KRW 4.15 billion in 2022, negative KRW 4.53 billion in 2023, negative KRW 380 million in 2024 and negative KRW 3.6 billion in 2025.
Quarterly revenue went from KRW 1.66 billion in Q4 2025 (up 31.5% quarter on quarter) to KRW 923 million in Q1 2026 (down 44.3%), KRW 1.38 billion in Q2 2026 (up 49.0%) and KRW 854 million in Q3 2026 (down 37.9%).
The operating loss was KRW 1.08 billion in Q3 2025, KRW 456 million in Q4 2025, KRW 1.43 billion in Q1 2026, KRW 924 million in Q2 2026 and KRW 1.85 billion in Q3 2026. Operating losses have been reported in each of the last five quarters, from Q3 2025 through Q3 2026.
One analysis links the decline in key product sales in Q1 2026, including Target Capture Kit and BTSeq Kit, to lower gross profit and operating profit.
The net loss attributable to controlling shareholders was KRW 814 million in Q4 2025, KRW 6.05 billion in Q1 2026, KRW 5.23 billion in Q2 2026 and KRW 2.99 billion in Q3 2026, totaling KRW 15.1 billion over the last four quarters.
The Q1 2026 net loss was far larger than that quarter's operating loss of KRW 1.43 billion, suggesting non-operating items weighed heavily.